The National Organization for Rare Disorders (NORD), along with The ALS Association, the Cystic Fibrosis Foundation, and the Muscular Dystrophy Association recently partnered again to host a virtual conversation on COVID-19 vaccines and safety. The event featured leaders from the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) providing key updates and insights from the administration, as well as addressing frequently asked questions on issues ranging from new virus strains to vaccine rollout plans, to the effect of vaccines on individuals with a rare disease.
On June 16, the speakers – Dr. Janet Woodcock, Acting Commissioner of the FDA; Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), FDA; Dr. Anne Schuchat, Principal Deputy Director of the Centers for Disease Control and Prevention (CDC); and Dr. Sara Oliver, Epidemiological Intelligence Service Officer, CDC – addressed the rare disease community in a conversation led by Dr. Ed Neilan, Chief Medical and Scientific Officer, NORD.
With vaccines readily available and cases declining, speakers and attendees gathered to ask and answer the new pressing questions surrounding the pandemic, engage on the next steps around vaccine distribution, and discuss vaccine hesitancy in both the general public and rare community. Learn more and view the full webinar on-demand now.
NORD continues to engage patients, physicians, experts, and its members on many crucial topics.
This webinar was a follow up to our January 15th webinar, COVID-19 Vaccines Update: FDA and CDC Leaders Address the Rare Disease Community. Read more about that virtual event at this link.
